



# ChAMP Empiric Antimicrobial Guidelines

For children with a beta-lactam allergy – refer to full guidelines

## RESPIRATORY / PNEUMONIA (HAP, CAP AND VAP)

<u>CAP &lt;1m</u>	IV gentamicin <b>AND</b> IV benzylpenicillin   Refer to <a href="#">neonatal guidelines</a>
	<i>Consider investigation and treatment for pertussis and/or Chlamydia trachomatis</i>
<u>CAP or aspiration pneumonia ≥1m</u>	PO <u>amoxicillin</u> 25mg/kg (max 1g) 8 hourly <b>OR</b> IV <u>benzylpenicillin</u> 50mg/kg (max 1.2g) 6 hourly
<u>Severe CAP ≥1m</u> <u>ICU OR fluid bolus ≥ 20mL/kg</u> <u>OR hypoxia (&lt;85% in air)</u>	IV <u>ceftriaxone</u> 50mg/kg (max 2g) once daily <b>AND</b> IV <u>vancomycin</u> 15mg/kg (max 750mg) 6 hourly <b>AND</b> PO/IV <u>azithromycin</u> 10mg/kg (max 500mg) once daily <b>Note</b> – Azithromycin for CAP should be restricted to 3 days treatment
<u>Hospital-acquired pneumonia (HAP) &gt;1month</u>	PO <u>amoxicillin/clavulanic acid</u> 25mg/kg (max 875mg amoxicillin component) 12 hourly <b>OR</b> IV <u>ceftriaxone</u> 50mg/kg (max 2g) once daily
<u>Severe HAP or VAP ≥1m</u> <u>ICU OR fluid bolus ≥ 20mL/kg</u> <u>OR hypoxia (&lt;85% in air)</u>	IV <u>piperacillin/tazobactam</u> 100mg/kg (max 4g) 8 hourly <b>AND</b> IV <u>vancomycin</u> 15mg/kg (max 750mg) 6 hourly
<u>Pertussis &lt;6m</u>	PO <u>azithromycin</u> 10mg/kg (max 500mg) once daily x 5 days
<u>Pertussis ≥6m</u>	PO <u>azithromycin</u> 10mg/kg (max 500mg) once daily on day 1 then 5mg/kg (max 250mg) once daily on days 2-5

## SEPSIS / BACTERAEMIA

<u>&lt; 1 month community acquired (meningitis excluded)</u>	IV gentamicin <b>AND</b> IV amoxicillin <b>CONSIDER</b> IV aciclovir	Refer to <a href="#">neonatal guidelines</a> for dosing in those <1 month.
<u>&lt; 1 month community acquired (meningitis not excluded)</u>	IV amoxicillin <b>AND</b> IV cefotaxime <b>ADD</b> gentamicin if unstable <b>CONSIDER</b> aciclovir	
<u>≥1m to ≤3 m fever &gt; 38°C without source</u>	Give IV <u>ceftriaxone</u> 50mg/kg (max 2g) once daily if bacteraemia suspected	
<u>≥ 1 month community acquired sepsis with haemodynamic instability</u>	IV <u>ceftriaxone</u> 50mg/kg (max 2g) 12 hourly <b>AND</b> IV <u>gentamicin</u> stat if unstable <b>CONSIDER</b> IV <u>vancomycin</u> 15mg/kg (max 750mg) 6 hourly <b>ADD</b> IV <u>aciclovir</u> if HSV encephalitis suspected	
<u>≥ 1 month Healthcare-associated sepsis</u>	IV <u>cefepime</u> 50mg/kg (max 2g) 8 hourly + IV <u>vancomycin</u> 15mg/kg (max 750mg) 6 hourly <b>CONSIDER</b> IV <u>gentamicin</u> stat if unstable	
<u>Fever +/- Neutropenia (Oncology patient) ≥ 1 month</u>	IV <u>cefepime</u> 50mg/kg (max 2g) 8 hourly +/- IV <u>vancomycin</u> 15mg/kg (max 750mg) 6 hourly <b>ADD</b> IV <u>gentamicin</u> stat if unstable	

## INTRA-ABDOMINAL SEPSIS, AGE ≥ 1 MONTH

<u>Peritonitis/ Appendicitis</u>	IV <u>amoxicillin/clavulanic acid</u> (refer to monograph for dose)
----------------------------------	---

## MENINGITIS – COMMUNITY ACQUIRED

<u>Meningitis &lt;1m</u>	IV cefotaxime <b>AND</b> IV benzylpenicillin <b>AND</b> aciclovir	Refer to <a href="#">neonatal guidelines</a>
<u>Meningitis ≥1m</u>	IV <a href="#">ceftriaxone</a> 50mg/kg (max 2g) 12 hourly <b>+</b> - IV <a href="#">vancomycin</a> 15mg/kg (max 750mg) 6 hourly	
<u>Encephalitis ≥1m</u>	IV <a href="#">aciclovir</a> <b>ADD</b> oral <a href="#">oseltamivir</a> 3mg/kg (max 75mg) 12 hourly for 5 days during flu season	

## URINARY TRACT INFECTION

<u>Systemically well, ≥ 3 months</u>	PO <a href="#">cefalexin</a> 20mg/kg (max 750mg) 8 hourly x 5 days
<u>Systemically unwell OR ≥ 1 to &lt; 3 months</u>	IV <a href="#">amoxicillin</a> 50mg/kg (max 1g) 6 hourly <b>AND</b> IV <a href="#">gentamicin</a> (refer to monograph for dose)

## SKIN AND SOFT TISSUE INFECTION, AGE ≥ 1 MONTH

<u>Mild</u>	PO <a href="#">cefalexin</a> 20mg/kg (max 750mg) 8 hourly <b>OR</b> , if able to tolerate capsules <a href="#">flucloxacillin</a> 12.5mg/kg (max 500mg) 6 hourly
<u>Moderate</u>	IV <a href="#">flucloxacillin</a> 50mg/kg (max 2g) 6 hourly
<u>Severe skin or soft tissue infection</u>	IV <a href="#">flucloxacillin</a> 50mg/kg (max 2g) 6 hourly <b>AND</b> IV <a href="#">vancomycin</a> 15mg/kg (max 750mg) 6 hourly <b>IF</b> shock or features of toxic shock syndrome <b>ADD</b> IV <a href="#">clindamycin</a> 10mg/kg (max 600mg) 6 hourly
<u>Bites, mild- moderate</u>	PO <a href="#">amoxicillin/clavulanic acid</a> 25mg/kg (max 875mg amoxicillin component) 12 hourly
<u>Bites, severe</u>	≥ 3months IV <a href="#">amoxicillin/clavulanic acid</a> 25mg/kg (max 1g) 8 hourly (refer to monograph for those <3months)

## OSTEOMYELITIS OR SEPTIC ARTHRITIS, AGE ≥ 3 MONTHS

<u>Uncomplicated</u>	IV <a href="#">flucloxacillin</a> 50mg/kg (max 2g) 6 hourly
<u>Uncomplicated (MRSA risk) OR severe/ multifocal/ ICU</u>	IV <a href="#">flucloxacillin</a> 50mg/kg (max 2g) 6 hourly <b>AND</b> IV <a href="#">vancomycin</a> 15mg/kg (max 750mg) 6 hourly

## EYES, EAR, NOSE & THROAT, AGE ≥ 3 MONTHS

<u>Mild periorbital cellulitis</u>	PO <a href="#">cefalexin</a> 20mg/kg (max 750mg) 8 hourly <b>OR</b> If sinusitis or HiB risk: <a href="#">amoxicillin/clavulanic acid</a> 25mg/kg (max 875mg amoxicillin component) 12 hourly
<u>Moderate periorbital cellulitis</u>	IV <a href="#">flucloxacillin</a> 50mg/kg (max 2g) 6 hourly <b>OR</b> If sinusitis or HiB risk: IV <a href="#">ceftriaxone</a> 50mg/kg (max 2g) once daily
<u>Severe periorbital or orbital cellulitis</u>	IV <a href="#">ceftriaxone</a> 50mg/kg (max 2g) once daily <b>AND</b> IV <a href="#">vancomycin</a> 15mg/kg (max 750mg) 6 hourly
<u>Acute mastoiditis</u>	IV <a href="#">ceftriaxone</a> 50mg/kg (max 2g) once daily
<u>Acute mastoiditis (with CSOM or history of Pseudomonas)</u>	IV <a href="#">piperacillin/tazobactam</a> 100mg/kg (max 4g) 8 hourly
<u>Otitis media (low risk CSOM)</u>	<b>Consider</b> PO <a href="#">amoxicillin</a> 15mg/kg (max 1g) 8 hourly x 5 days Refer to full <a href="#">guideline</a> for patients at high risk of CSOM
<u>Tonsillitis</u>	<b>Consider</b> PO <a href="#">phenoxymethypenicillin</a> 15mg/kg (max 500mg) 12 hourly x 10 days

Summarised information from ChAMP Empiric Guidelines: Approved March 2022, Review Date March 2025